Disease · MONDO_0018908
Comparisons in its trials151
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 151
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Idelalisib + Bendamustine + Rituximab vs Placebo + Bendamustine + Rituximab: serious adverse events | 229 of 317 | 58 of 155 | 472 | NCT01732926 | Trial comparisons |
| Ofatumumab vs Rituximab: Number of Participants With Complete Response (CR) | 36 of 219 | 44 of 219 | 438 | NCT01200589 | Trial comparisons |
| Ofatumumab vs Rituximab: Number of Participants With Overall Response (OR) | 110 of 219 | 144 of 219 | 438 | NCT01200589 | Trial comparisons |
| Ofatumumab vs Rituximab: Progression-free Survival (PFS) - Number of Participants With PFS Events | 114 of 219 | 117 of 219 | 438 | NCT01200589 | Trial comparisons |
| Ofatumumab vs Rituximab: Number of Deaths | 28 of 219 | 30 of 219 | 438 | NCT01200589 | Trial comparisons |
| Ofatumumab vs Rituximab: Number of Participants With Infusion Related Adverse Events Due to Study Drug | 178 of 217 | 112 of 218 | 435 | NCT01200589 | Trial comparisons |
| Ofatumumab vs Rituximab: Number of Participants With Myelosuppression Adverse Events | 24 of 217 | 41 of 218 | 435 | NCT01200589 | Trial comparisons |
| Ofatumumab vs Rituximab: Number of Participants With Infection Related Adverse Events | 69 of 217 | 81 of 218 | 435 | NCT01200589 | Trial comparisons |
| Ofatumumab vs Rituximab: serious adverse events | 38 of 217 | 37 of 218 | 435 | NCT01200589 | Trial comparisons |
| Mitoxantrone, Chlorambucil, Prednisolone (MCP) vs Rituximab + MCP: serious adverse events | 20 of 177 | 18 of 183 | 360 | NCT00269113 | Trial comparisons |
With EPOCH-R (Etoposide, Doxorubicin, Prednisone, Cyclophosphamide and Rituximab) vs EPOCH Alone (Etoposide, Doxorubicin, Prednisone, and Cyclophosphamide): Overall Response (Complete Response + Partial Response) | 216 of 235 | 94 of 112 | 347 | NCT00001337 | Trial comparisons |
With EPOCH-R (Etoposide, Doxorubicin, Prednisone, Cyclophosphamide and Rituximab) vs EPOCH Alone (Etoposide, Doxorubicin, Prednisone, and Cyclophosphamide): Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0) | 235 of 235 | 112 of 112 | 347 | NCT00001337 | Trial comparisons |
| With EPOCH-R (Etoposide, Doxorubicin, Prednisone, Cyclophosphamide and Rituximab) vs EPOCH Alone (Etoposide, Doxorubicin, Prednisone, and Cyclophosphamide): Progression Free Survival (PFS) | 73 of 235 | 41 of 112 | 347 | NCT00001337 | Trial comparisons |
| With EPOCH-R (Etoposide, Doxorubicin, Prednisone, Cyclophosphamide and Rituximab) vs EPOCH Alone (Etoposide, Doxorubicin, Prednisone, and Cyclophosphamide): deaths from any cause | 28 of 235 | 13 of 112 | 347 | NCT00001337 | Trial comparisons |
| With EPOCH-R (Etoposide, Doxorubicin, Prednisone, Cyclophosphamide and Rituximab) vs EPOCH Alone (Etoposide, Doxorubicin, Prednisone, and Cyclophosphamide): serious adverse events | 146 of 235 | 44 of 112 | 347 | NCT00001337 | Trial comparisons |
| Inotuzumab Ozogamicin+Rituximab vs Rituximab+Gemcitabine or Rituximab+Bendamustine: serious adverse events | 61 of 164 | 63 of 167 | 331 | NCT01232556 | Trial comparisons |
| Arm A: DRL_RI vs Arm B: MabThera®: deaths from any cause | 3 of 162 | 2 of 153 | 315 | NCT03976102 | Trial comparisons |
| Arm A: DRL_RI vs Arm B: MabThera®: serious adverse events | 22 of 162 | 21 of 153 | 315 | NCT03976102 | Trial comparisons |
| G-CSF Plus Plerixafor vs G-CSF Plus Placebo: serious adverse events | 8 of 150 | 10 of 145 | 295 | NCT00103610 | Trial comparisons |
| Idelalisib + Rituximab vs Placebo + Rituximab: serious adverse events | 103 of 198 | 11 of 95 | 293 | NCT01732913 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0018908/comparisons